Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: A phase I, open-label, noncomparative clinical trial in healthy volunteers

Clinical Therapeutics

Volumn 27, Issue 7, 2005, Pages 1043-1049

  Ponte, Carrnen ^a   Gracia, Matilde ^a   Giménez, Maria José ^b   Aguilar, Lorenzo ^b,e   Maín, Carmen Martínez ^a   Carpintero, Yolanda ^c   Huelves, Lorena ^a   Carcas, Antonio ^d   Del Prado, Gemma ^a   Soriano, Francisco ^a  

^a Jimenez Diaz Foundation   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c GLAXOSMITHKLINE   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e SCHOOL OF MEDICINE   (Spain)

Author keywords

Amoxicillin clavulanic acid; Clinical study; Escherichia coli; Phase I study; Sustained release; Urinary killing activity

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; CLINICAL TRIAL; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DRUG EXCRETION; DRUG URINE LEVEL; EX VIVO STUDY; HUMAN; INOCULATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; URINALYSIS; URINARY TRACT INFECTION;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLAVULANIC ACID; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 24344498222     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.07.001     Document Type: Article

References (18)

1. Hooton TM The epidemiology of urinary tract infection and the concept of significant bacteriuria Infection. 18 Suppl. 2 1990 S40 S43
2. Sanford JP Urinary tract symptoms and infections Annu RevMed. 26 1975 485 498
3. Stamm WE, and Hooton TM Management of urinary tract in fections in adults N Engl J Med. 329 1993 1328 1334
4. Sobel JD, and Kaye D Urinary tract infections Mandell GL Bennett JE Dolin R Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2005 Churchill Livingstone Philadelphia, Pa 875 905
5. Ena J, Lopez-Perezagua MM, and Martinez-Peinado C Emergence ofciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones Diagn Microbiol Infect Dis. 30 1998 103 107
6. [in Spanish] Andreu A, Alos JI, Gobernado M for the Group Cooperativo Español para el Estudio de la Sensibilidad Antimicrobiana de los Patogenos Urinarios Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: A nationwide surveillance study Enferm Infecc Microbiol Clin. 23 2005 4 9
7. Publication no. M100-S15 Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement 2005 CLSI Wayne, Pa
8. Kaye CM, Allen A, and Perry S The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate Clin Ther. 23 2001 578 584
9. Alou L, Aguilar L, and Sevillano D Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically en-hanced 2000/125 mg co-amoxiclav to healthy volunteers J Antimicrob Chemother. 55 2005 742 747
10. Aguilar L, Balcabao IP, and Salva P Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers Antimicrob Agents Chemother. 40 1996 17 21
11. Del Rio G, Dalet F, and Aguilar L Single-dose rufloxacin versus 3-daynorfloxacin treatment of uncomplicated cystitis: Clinical evaluation and pharmacodynamic considerations Antimicrob Agents Chemother. 40 1996 408 412
12. Klastersky J, Daneau D, Swings G, and Weerts D Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections J Infect Dis. 129 1974 187 193
13. Bronner S, Murbach V, and Peter JD Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics humanpharmacokinetics Antimicrob Agents Chemother. 46 2002 3782 3789
14. Bush K, Jacoby GA, and Medeiros AA A functional classification scheme for beta-lactamases and its correlation with molecular structure Antimicrob Agents Chemother. 39 1995 1211 1233
15. Naber KG Treatment options for acute uncomplicated cystitis in adults J Antimicrob Chemother. 46 Suppl 1 2000 23 27
16. Gracia M, Ponte C, and Soriano F Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibility to the compounds Int J Antimicrob Agents. 25 2005 352 353
17. Sevillano D, Calvo A, and Gimenez MJ Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an invitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation J Antimicrobial Chemother. 54 2004 1148 1151
18. Thorburn CE, Molesworth SJ, Sutherland R, and Rittenhouse S Post-antibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate Antimicrob Agents Chemother. 40 1996 2796 2801